SIM
MBRX icon

Sonora Investment Management’s Moleculin Biotech MBRX Stock Holding History

Sonora Investment Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4
Closed -$11K – 1702
2019
Q3 		$11K Buy
+4
New +$10.3K ﹤0.01% 1136

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sonora Investment Management's MBRX Position: Q4 2019 in Review

Sonora Investment Management sold out of Moleculin Biotech (MBRX) in Q4 2019, closing a stake of 4 shares — an estimated $11K sold.

Sonora Investment Management first reported a position in MBRX in Q3 2019 and held it in 1 quarter. The position peaked at $11K in Q3 2019. 22 funds tracked by Wall St. Rank hold MBRX as of Q4 2019.

  • Sonora Investment Management reported no remaining Moleculin Biotech position as of Q4 2019 after selling out during the quarter.
  • Sonora Investment Management sold 4 Moleculin Biotech shares in Q4 2019, an estimated $11K.
  • Sonora Investment Management first reported a position in Moleculin Biotech in Q3 2019 and held it in 1 quarter.
  • Sonora Investment Management's Moleculin Biotech position peaked at $11K in Q3 2019.
  • 22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2019.

Based on Sonora Investment Management's 13F filing for Q4 2019, filed 17 Jan 2020.